In vivo pharmacodynamics (PD) evaluations involve assessing thebiological effects of a drug within a living organism. These evaluations are designed to determine the drug's efficacy, mechanism of action, therapeutic index, and potential side effects. Typically conducted using animal models, in vivo PD evaluations help researchers understand how a drug interacts with physiological systems, its relationship to dosage, and the overall impact on health outcomes. Such studies are essential for drug development, aiding in the transition from preclinical research to clinical trials.
The GenoBioTX's Metabolic/cardiovascular disease evaluation platform is led by a team of experienced experts. It features a variety of classic metabolic models and has strong capabilities in model development. The platform offers comprehensive drug evaluation services, including drug metabolism, imaging, behavioral studies, histopathology, and molecular biomarker detection.
The DIO high-fat diet-induced animal obesity model is similar to human obesity and effectively reflects the pathogenesis of obesity in humans, such as gradual weight gain and subsequent insulin resistance. This model can be used to study metabolic diseases like obesity, diabetes, and fatty liver.
The GAN (Gubra-Amylin NASH) diet is a modified, trans-fat-free, high-fat, high-cholesterol, and high-fructose feed. The MASH animal model induced by this diet better simulates the occurrence of human diseases and demonstrates good translational relevance in terms of physiology, metabolism, and histopathology. Research has shown that GLP-1 can reduce hepatic steatosis and hepatocyte injury after binding to its receptor in the liver, as well as alleviate inflammatory responses and fibrosis in MASH. Semaglutide, targeting this pathway, has shown positive results in clinical trials for the treatment of MASH.
GLP-1R belongs to the B family of G protein-coupled receptors and is a glucagon-like peptide-1 (GLP-1 receptor. its primary function is to bind with GLP-1 to regulate blood glucose levels. GLP-1R agonist drugs are one of the mainstream choices for diabetes treatment, and recent studies have shown that these drugs also have excellent weight loss effects. The GLP-1R humanized mice developed by GenoBioTX are a reliable option for preclinical validation of GLP-1R targeted drugs.
Please fill in the order form and we will contact you within 2 working days.
